發送短信 : Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer

  _  _     ______    _____     ______  __    __  
 | \| ||  /_   _//  /  ___||  /_   _// \ \\ / // 
 |  ' ||   -| ||-  | // __     -| ||-   \ \/ //  
 | .  ||   _| ||_  | \\_\ ||   _| ||_    \  //   
 |_|\_||  /_____//  \____//   /_____//    \//    
 `-` -`   `-----`    `---`    `-----`      `